Ultragenyx Pharmaceutical | RARE - Debt


Ultragenyx Pharmaceutical reported $36M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Immunic USD 0 0 Jun/2024
Insmed USD 725.8M 1.82M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Kyowa Hakko Kirin JPY 28.75B 5.04B Dec/2024
MacroGenics USD 36.51M 500K Mar/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026